ArticleCureus2025
Lercanidipine-Induced Hyponatremia in Elderly Patients: A Not-So-Rare Complication.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyponatremia, defined as serum sodium concentration below 135 mmol/L, is the most common electrolyte disturbance in the hospitalized geriatric population and is associated with significant morbidity and mortality. While various medications are known to contribute to hyponatremia, calcium channel blockers (CCBs) are not considered. Here we present a case of an elderly patient who developed severe hyponatremia (serum sodium 117 mmol/L). Despite standard interventions in an intensive care setting, the patient's hyponatremia proved resistant to correction. Medication review revealed recent initiation of lercanidipine for hypertension management. Upon discontinuation of lercanidipine, the patient's hyponatremia and confusion resolved. Current NHS guidelines do not recommend routine electrolyte monitoring when prescribing CCBs, unlike recommendations for ACE inhibitors and ARBs. We recommend implementing routine electrolyte monitoring when initiating CCBs in this vulnerable population group to prevent potentially life-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.